Navigation Links
Repligen Licenses Rights to Use of HDAC3 Inhibitors for Memory Disorders
Date:1/20/2011

WALTHAM, Mass., Jan. 20, 2011 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has entered into an exclusive license agreement with the University of California, Irvine (UCI) for a patent application covering the use of histone deacetylase 3 (HDAC3) inhibitors for the treatment of disorders involving preservation or extinction of memory including Alzheimer's disease, memory impairment and post traumatic stress disorder.  The patent application is based on work conducted at UCI by Dr. Marcelo A. Wood, which demonstrated that one of Repligen's HDAC3 inhibitors improved both the acquisition and persistence of long-term memory in an animal model.  These data were published in the January 12th issue of The Journal of Neuroscience in a manuscript entitled "HDAC3 Is a Critical Negative Regulator of Long-Term Memory Formation" (McQuown, S., et al., J. Neurosci. (2011) 31:764 –774).  Under the terms of the license agreement, UCI will receive an upfront payment, development milestones and royalties upon successful commercialization of an HDAC3 inhibitor for certain memory disorders.  Upon issue, the patent will remain in force until 2031 prior to any regulatory extensions.

"These new data indicate that HDAC3 inhibitors should be further evaluated for use in a variety of disorders in which the acquisition or extinction of a long-term memory is a factor," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "We intend to continue to investigate the potential of our selective HDAC3 inhibitors in a variety of disease models."

The manuscript published in The Journal of Neuroscience examined the role of HDAC3 inhibitors in long-term memory using a combined genetic and pharmacologic approach.  In the study, a genetic approach was used to delete HDAC3 in the hi
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
6. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
7. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
8. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
9. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
10. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
11. Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
(Date:10/30/2014)... nebulizer is a medical device used for the treatment ... converts liquid medication into mist or aerosol. Thus, the ... patient when inhaled through the mouth or a face ... devices powered by electric current and rechargeable batteries. Factors ... fibrosis and growing number of geriatric population worldwide support ...
(Date:10/30/2014)... Oct. 29, 2014   ViaDerma, Inc. ... bringing new products to market, is committed to ... has developed an innovative, patent-pending dual carrier transdermal ... of pharmaceutical active ingredients to penetrate the skin ... therapy. The transdermal delivery method also overcomes microbial ...
Breaking Medicine Technology:Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... 1b study planned for mid 2008 with Phase 2 development ... to begin late in 2008 or in early ... NUVO ) today announced positive results from the Phase 1,proof-of-concept ... offset of anticoagulation after,a single bolus dose with a favorable safety ...
... Erythematosus ... ... (Nasdaq: RIGL ) announced today that its lead product,candidate, R788, ... reported in a recently published,study of the drug candidate. R788 (fostamatinib ...
Cached Medicine Technology:Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 2Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 3Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 4Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 2Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 3Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 4
(Date:10/30/2014)... Chicago, IL (PRWEB) October 30, 2014 Dr. ... launched a new website for his practices; OB GYN ... Chicago, IL . This website contains important information about ... covers as well as downloadable patient forms in English and ... use and the service pages on the website provide Dr. ...
(Date:10/30/2014)... Rock Hill, South Carolina (PRWEB) October 30, 2014 ... a muscle, and should be more vigorously exercised to ... Grewal. He recently authored the book ‘Dementia Express: Lose ... , The book uses counterintuitive reasoning and sometimes conflicting ... an obstacle course for the mind, a reader must ...
(Date:10/30/2014)... who used stem cells to create miniature human stomachs ... new way to learn more about the development and ... pluripotent stem cells -- which can become any type ... functional miniature stomachs, to study infection by H. ... stomach cancer. The miniature stomachs offer many research ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Americans, opinions ... political lines, a new study finds. Democratic voters ... (ACA), according to the researchers. Almost three-quarters of Democrats ... ACA. Thirty percent want Congress to implement the current ... of the ACA. Among Independent voters, one-third want ...
(Date:10/29/2014)... women at first acted surprised. Some insisted the blood tests ... not used the study products assigned to them as participants ... likely consequence, did not find any of the three products ... were among 127 former VOICE participants who, as part of ... in in-depth interviews and/or focus group discussions after learning the ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 3
... of hormone worsened respiratory disease , , THURSDAY, Nov. 20 ... may explain why women with cystic fibrosis tend to ... at the University of North Carolina report. , , ... 20 issue of the Journal of Clinical Investigation ...
... Reno,s Downtown Ballroom was transformed into a Cirque style extravaganza ... ballroom to help raise funds for one of Reno,s most ... residents and many of Nevada,s prominent leaders, including Nevada Governor ... To view the Multimedia News Release, go to: ...
... Nov. 20 Precyse Solutions, the leader in,driving ... management solutions, was recognized by the Eastern Technology,Council ... at the 16th,Enterprise Award Gala held at the ... top technology and life sciences companies and entrepreneurs. ...
... at risk for hospital visits of their own , , THURSDAY, ... for a loved one with Alzheimer,s results in 25 percent ... hospital visit every six months, says an Indiana University study. ... an Alzheimer,s patient is difficult, but the Indiana University researchers ...
... Quality Care , ARLINGTON HEIGHTS, Ill., Nov. 20 ... cannot afford to cut corners on quality of care, warns ... thing to temporarily substitute fillers for facelifts, ASPS says the ... professional training. This concern was discussed recently at the ASPS ...
... People are often reluctant to undergo a routine but ... be fatal. According to the American Cancer Society, colon ... American men and women and kills about 50,000 Americans ... cancer have no symptoms or family history," says Prof. ...
Cached Medicine News:Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 2Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 3Health News:Photos: Nevada's Saint Mary's Regional Medical Center Raises $1.3 Million During Centennial Soiree 2Health News:Precyse Solutions Honored as 'Technology Company of the Year' 2Health News:When the Caregiver Becomes the Patient 2Health News:Caution Urged as Patients Seek Deals on Cosmetic Surgery 2Health News:A simple blood test for colon cancer 2
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
Inquire...
... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
... Combines BchiVac V-500 with Vacuum ... Efficiently controls vacuum levels from ... pump designed to handle most vacuum applications. ... up to two rotary evaporators Laboratory ...
Medicine Products: